Gennova has developed differentiating technologies across three established biomanufacturing platforms for process and product development of bio-therapeutics and vaccines:
Gennova has designed mammalian production cell lines that can survive more than 90 days in a packed bed perfusion-based bioreactor system which allows for a continuous biomanufacturing approach. This process outpaces the product generation by traditional processes and is highly economical. It results in low risk and losses in case of failure and has low levels of process-related impurities. The benefit of this approach is demonstrated by our commercialized products- Elaxim®, TENECTASE® and Vintor®.
| Brand Name | Elaxim® |
| Indication | Acute Myocardial Infarction (AMI) |
| INN | Tenecteplase |
| Strength |
Elaxim® 30 mg, Elaxim® 40 mg, Elaxim® 52.5 mg |
| Launch year | 2007 |
| Brand Name | TENECTASE® |
| Indication | Acute Ischemic Stroke (AIS) |
| INN | Tenecteplase |
| Strength | TENECTASE® 20 mg |
| Launch year | 2016 |
| Brand Name | Vintor® |
| Indication | Anemia due to Chronic Renal Failure (CRF) |
| INN | Erythropoeitin |
| Strength |
Vintor® - 2000 IU, Vintor® - 3000 IU, Vintor® - 4000 IU, Vintor® - 6000 IU, Vintor® - 10000 IU, Vintor® - 20000 IU |
| Launch year | 2007 |
Development of tenecteplase for stroke was recognized by the Department of Biotechnology (DBT), Govt. of India for the ‘Biotech product, process development and commercialization award 2019’. Additionally, this ‘Make in India’ product has found its way in the list of drugs for emergency care for stroke management in the guideline – ‘Prevention and Management of Stroke’, (2019 and updated in 2024) issued by the Ministry of Health and Family Welfare, Govt. of India.
Gennova’s innovation around high cell density fermentation and genetic manipulations for its microbial products have successfully culminated in the development and commercialization of Xgrast® and PEGEX® to treat febrile neutropenia after chemotherapy in cancer patients and is one of the leading manufacturers of these biologics in India. Continuing its efforts on innovative pegylation processes, Gennova was the first Indian company to develop generic pegaspargase, Hamsyl®, for use in an orphan indication, acute lymphoblastic lymphoma (ALL). Rising to the call of clinicians, Gennova launched Hamsyl® Junior in 2024, which is first-of-its-kind paediatric pack size of pegaspargase and proved to be a significant milestone in advancing paediatric cancer care for Indian children suffering from ALL.
| Brand Name | Xgrast® |
| Indication | Febrile Neutropenia |
| INN | Filgrastim (GCSF) |
| Strength |
Xgrast® 150 µg, Xgrast® 300 µg, Xgrast® 480 µg |
| Launch year | 2010 |
| Brand Name | PEGEX® |
| Indication | Febrile Neutropenia |
| INN | PEG-filgrastim (PEG-GCSF) |
| Strength | PEGEX® 6 mg/ 0.6 ml |
| Launch year | 2010 |
| Brand Name | Hamsyl® |
| Indication | Acute Lymphoblastic Leukemia (ALL) |
| INN | Pegaspargase |
| Strength | Hamsyl® 3750 IU/ 5ml |
| Launch year | 2014 |
| Brand Name | Hamsyl®Junior |
| Indication | Acute Lymphoblastic Leukemia (ALL) |
| INN | Pegaspargase-paediatric pack |
| Strength | Hamsyl® Junior 1500 IU/ 2ml |
| Launch year | 2024 |
Gennova has built a cutting-edge mRNA-based production platform for developing, manufacturing, and commercializing next- generation biotherapeutics. mRNA-based therapeutics are non-infectious, non-integrating, and cell-free, enabling scalable and efficient production.
At the core of Gennova’s innovation is its self-amplifying mRNA (sa-mRNA) strategy, coupled with a robust delivery system that enhances storage stability. This breakthrough approach led to the development of India’s first mRNA vaccines—GEMCOVAC®-19 (targeting the Wuhan strain) and GEMCOVAC®-OM (Omicron-specific), both approved by CDSCO for Restricted Use in Emergency Situations in 2022 and 2023, respectively. These are also the world’s first thermostable mRNA vaccines against COVID-19.
